Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
about
Social implications of rheumatic diseasesCardiovascular risk in rheumatoid arthritis: assessment, management and next stepsIs the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritisGlucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritisWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studiesThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.Evaluation of Audiometric Test Results to Determine Hearing Impairment in Patients with Rheumatoid Arthritis: Analysis of Data from the Korean National Health and Nutrition Examination Survey.Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDsAnti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients[How do register data support clinical decision-making?].Effects of PVA coated nanoparticles on human immune cellsPredictors of diastolic dysfunction in rheumatoid arthritisComparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administrationIndirect costs of rheumatoid arthritisRheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan.Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort studyIncreased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritisWhen and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceDefining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force."Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements.Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients.Glucocorticoids improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis.Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study.Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents.Effect of acute and chronic glucocorticoid therapy on insulin sensitivity and postprandial vascular function.[How frequent are musculoskeletal diseases in Germany?].Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.Simple screening tools predict death and cardiovascular events in patients with rheumatic disease.Adaptation to inflammatory rheumatic disease: Do illness representations predict patients' physical functioning over time? A complex relationship.Rituximab for recurrent IgA nephropathy in kidney transplantation: A report of three cases and proposed mechanisms.Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study.
P2860
Q26741003-B45D5437-AAE1-4A47-8462-D2D277BD0A31Q26744334-FEC0F101-0346-452D-A362-54010B26D97AQ26746659-262FC9A8-CB00-44B2-993A-1084C2C5C0E0Q28072472-0CBFA041-07DA-4C7A-8816-72B5B8E365ABQ28074148-D1A2FB84-48DE-4725-9E05-E2C833E5869AQ28078550-8302B4EA-5510-4E8A-827E-69FCC3F74E50Q30397234-788F9951-AED0-4F9D-9CB6-F27EF43F6523Q31043666-4083BB94-51F3-433C-9939-4FE7B9B71ED9Q31122982-AEBE3E82-0433-4084-A1C8-1485E8EB8A9FQ31136476-19B32B7E-AB45-4041-8958-9AD73AEAAA4CQ33731689-1751D47B-AB3A-4303-8C89-0DD4F691611EQ33865776-1BC0F08C-5B68-411E-B832-6F75CF164D90Q35585867-D9DD0C7A-AA9A-4C45-9324-4629BAE4B286Q35605942-E0FC4A11-C32B-4B33-84F2-6AD763E2ECA2Q35620858-422E069A-2117-41ED-8D8D-F18AA5BC7BE3Q36220832-5B396C65-0687-4CBC-A297-FAEB65BCF375Q36818355-B353B18E-8860-4FEA-ABD4-62903067CFF3Q36842488-CFE02773-3FAD-4B73-B106-20F4F6871935Q37094851-F576D87B-FA79-4665-807E-DD7B77419790Q37167818-32B3174E-BDE2-48B7-BBC5-0B60B99CC36CQ37341911-A9D2CE2C-93C9-4A37-A3FC-575B4E9A7E87Q37617747-E2B7CEBB-3510-4F52-AB24-7C1AE0955ACCQ38211695-BF3DC837-2397-477F-B19A-96AC929A160BQ38305522-55C199AA-716A-4B6E-A946-33A6D4340E8CQ38476881-8057FDA0-3B74-442A-803E-30FA51100192Q38757421-FA238F5A-3CBD-4F02-A541-ADF454095396Q38777227-34E3E69C-1D36-4930-ADB9-54A6CD26684AQ38797087-E2117880-AD9A-47D1-944F-F11D14245399Q38820248-FFA6EC3B-102D-426B-8EDD-E5A33F25290BQ38983832-D06DBD91-7E3A-469B-A748-3CA200A44B0AQ39248083-B3383EA3-629E-4E81-8D5F-1C0B9D1A0719Q39372731-AAE32F2E-7347-46D1-A9B8-E0F0C1AFA8FCQ40402211-F06FC47C-C708-4A93-A747-9D122B57F53AQ40770683-B5D4F10D-36A5-412A-90F3-8C0A8C94EB84Q41348100-EDBBADE5-906A-4BEC-8E65-DFBD838EB4ECQ48152632-F0C5F69B-612D-49E0-A8E8-C44ECBCF93DBQ49945512-FE1FEAC8-AE10-4568-90B1-7D6110A2E2E1Q50270460-C3C3EC88-3382-4B90-9492-83F09E1F4313Q51076666-1861FD0C-167A-4150-8B30-97A60C370ADEQ52848191-FA846572-9323-49FB-BBE6-7A9A4CA0C9B4
P2860
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@ast
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@en
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@nl
type
label
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@ast
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@en
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@nl
prefLabel
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@ast
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@en
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@nl
P2093
P2860
P1476
Mortality in rheumatoid arthri ...... TNFα inhibitors and rituximab
@en
P2093
Angela Zink
Anja Strangfeld
Bernhard Manger
Dagmar Pattloch
Joachim Listing
Jörn Kekow
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204021
P407
P577
2013-11-29T00:00:00Z